精准医疗企业Billiontoone近日宣布，其创新液体活检产品Northstar Select®已被正式选定为国立癌症研究中心东医院开展的Lc-Scrum-TRY临床研究项目的新型检测工具。该举措标志着液体活检技术在肿瘤临床研究中的应用迈出关键一步。
此次合作将依托Northstar Select®的高灵敏度特性，对参与Lc-Scrum-TRY研究的肺癌患者进行循环肿瘤DNA监测。该技术能通过血液样本实现微转移病灶的早期识别，为动态评估治疗方案有效性提供重要依据。
国立癌症研究中心东医院作为日本顶尖肿瘤研究机构，其主导的Lc-Scrum-TRY项目旨在建立肺癌治疗响应评估新范式。引入Billiontoone的液体活检技术，有望突破传统组织活检的时空局限性，实现治疗过程中肿瘤基因演变的连续追踪。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.